Commentary: Novel therapies for cancer: Why dirty might be better

被引：45

作者：

Fojo, Tito ^{[1
]}

机构：

[1] NCI, Med Oncol Branch, Bethesda, MD 20892 USA

来源：

ONCOLOGIST | 2008年 / 13卷 / 03期

关键词：

targeted agents; drug resistance; tyrosine kinase inhibitors; imatinib; Bcr-Abl; c-KIT; epidermal growth factor receptor (EGFR) inhibitors; gefitinib; erlotinib; stem cells;

D O I：

10.1634/theoncologist.2007-0090

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：277 / 283

页数：7

共 61 条

[1]

Development of farnesyl transferase inhibitors: A review [J].

Appels, NMGM ;

Beijnen, JH ;

Schellens, JHM .

ONCOLOGIST, 2005, 10 (08) :565-578

[2]

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[3]

Barlow SB, 2002, J CELL SCI, V115, P3469

[4]

Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].

Bradeen, Heather A. ;

Eide, Christopher A. ;

O'Hare, Thomas ;

Johnson, Kara J. ;

Willis, Stephanie G. ;

Lee, Francis Y. ;

Druker, Brian J. ;

Deininger, Michael W. .

BLOOD, 2006, 108 (07) :2332-2338

[5]

Buchdunger E, 1996, CANCER RES, V56, P100

[6]

The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma [J].

Choueiri, Toni K. ;

Bukowski, Ronald M. ;

Rini, Brian I. .

SEMINARS IN ONCOLOGY, 2006, 33 (05) :596-606

[7]

Come SE, 2005, CLIN CANCER RES, V11, p861S

[8]

4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER [J].

COOMBES, RC ;

GOSS, P ;

DOWSETT, M ;

GAZET, JC ;

BRODIE, A .

LANCET, 1984, 2 (8414) :1237-1239

[9]

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients [J].

Cortes-Funes, H ;

Gomez, C ;

Rosell, R ;

Valero, P ;

Garcia-Giron, C ;

Velasco, A ;

Izquierdo, A ;

Diz, P ;

Camps, C ;

Castellanos, D ;

Alberola, V ;

Cardenal, F ;

Gonzalez-Larriba, JL ;

Vieitez, JM ;

Maeztu, I ;

Sanchez, JJ ;

Queralt, C ;

Mayo, C ;

Mendez, P ;

Moran, T ;

Taron, M .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1081-1086

[10]

hOCT 1 and resistance to imatinib [J].

Crossman, LC ;

Druker, BJ ;

Deininger, MWN .

BLOOD, 2005, 106 (03) :1133-1134

← 1 2 3 4 5 6 7 →